In addition, the current study revealed that clinically available drugs (DEX, PTN, RES, MCZ, and DAS) with CAR‐agonistic effects have anti‐inflammatory effects and hepatoprotective effects against endotoxin‐induced liver injury; the results obtained from DEX, DAS, and RES are consistent with previous findings.[35, 36, 37] Therefore, CAR activation with agonists after sepsis onset may be a promising strategy for the management of endotoxemic liver disease. The gene discussed is NR1I3; the disease is Sepsis.